Clinical study on treatment of cirrhosis by different dosages of Salvianolic acid B and Salvia Injection
AIM: To find the optimal dosage of Salvianolic acid B( SAB) and Salvia Injection(SI) in treating cirrhosis with hepatitis B virus (HBV) and to compare the treatment effects between Salvianolic acid B and Salvia Injection. METHODS: One hundred and fifty cirrhosis patients with HBV were divided into compensatory group (A) and decompensated ( B) cirrhosis group. In each group,the patients were randomly subdivided into large dosage SAB group(80 mg),middle dosage SAB group(60 mg),small dosage SAB group(40 mg),SI group (24 mL) and control group. The clinical symptoms,signs,liver functional indexes (ALT and TBil) and liver fibrosis indexes [procollagen type Ⅲ (PCⅢ),collagen type Ⅳ(CⅣ) and hyaluronic acid(HA)] were measured. RESULTS: Different dosages of SAB and SI all improved the clinical symptoms and declined the levels of ALT,TBil,PC Ⅲ,C Ⅳ and HA(P<0.05). Treatment with large and middle dosages of SAB showed the best efficacy,superior to that of small dosage of SAB and SI (P < 0.05 ),but no significant difference was found between the efficacy of the latter two( P > 0.05). The efficacy of SAB and SI in compensatory cirrhosis group was better than that in decompensated cirrhosis group ( P < 0. 05 ). CONCLUSION: Salvianolic acid B(SAB) has better efficacy than Salvia Injection in treatment of cirrhosis with HBV. Both have better effect on patients with compensated rather than decompensated cirrhosis. No significant difference is found between large dosage(80 mg) and middle dosage(60 mg) of SAB.
cirrhosisSalvianolic acid B injectionsalvia injectionadministration and dosage
NETL
NSTL
万方数据
维普
